ArticleInternational journal of nanomedicine2010
Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines.
Article in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 77 citations in OpenAlex.
- Advanced Nanomaterials Functionalized with Metal Complexes for Cancer Therapy: From Drug Loading to Targeted Cellular Response.Pharmaceuticals (Basel, Switzerland) · 2025Review
- New Food Preservation candidate Zataria multiflora endrimer Synthesis and Antimicrobial Assessment.Archives of Razi Institute · 2024Article
- Inhibition of HIV-1 infection with curcumin conjugated PEG-citrate dendrimer; a new nano formulation.BMC complementary medicine and therapies · 2024Article
- Article
- Antimalarial Effects of Nano Chloroquine Loaded Curcumin In vivo.Infectious disorders drug targets · 2024Article
- Biological Effects in Cancer Cells of Mono- and Bidentate Conjugation of Cisplatin on PAMAM Dendrimers: A Comparative Study.Pharmaceutics · 2023Article
- Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.International journal of molecular sciences · 2022Review
- Antiplasmodial Effect of Nano Dendrimer G2 Loaded with Chloroquine in Mice Infected with Plasmodium berghei.Acta parasitologica · 2022Article
- Lamivudine-conjugated and efavirenz-loaded G2 dendrimers: Novel anti-retroviral nano drug delivery systems.IET nanobiotechnology · 2021Article
- Novel chloroquine loaded curcumin based anionic linear globular dendrimer G2: a metabolomics study onParasitology · 2020Article
- PEG-Citrate dendrimer second generation: is this a good carrier for imaging agentsIET nanobiotechnology · 2019Article
- Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.Journal of materials science. Materials in medicine · 2018Article
- Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected withOpen access Macedonian journal of medical sciences · 2018Article
- AS1411 Aptamer-Anionic Linear Globular Dendrimer G2-Iohexol Selective Nano-Theranostics.Scientific reports · 2017Article
- GdContrast media & molecular imaging · 2017Article
- Novel chlorambucil-conjugated anionic linear-globular PEG-based second-generation dendrimer: in vitro/in vivo improved anticancer activity.OncoTargets and therapy · 2016Article
- Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity.Journal of materials science. Materials in medicine · 2015Article
- Nanotechnology-applied curcumin for different diseases therapy.BioMed research international · 2014Review
- Diethylentriaminepenta acetic acid glucose conjugates as a cell permeable iron chelator.Journal of pharmacology & pharmacotherapeutics · 2014Article
- Nanocarriers for delivery of platinum anticancer drugs.Advanced drug delivery reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to their unique properties, Anticancer dendrimer-based drugs have been displaying promising results in both in vitro and in vivo in the treatment of cancerous cells, as compared to the traditional polymers. In this report, two conjugates (G1+Pt and G2+Pt) of cisplatin [cis-diaminedichloroplatinum; (CDDP)] with two generations (G1, G2) of a biocompatible anionic dendrimer were prepared in an aqueous media. Their potential cytotoxic effects, in two sensitive cancer cell lines HT1080 and CT26 together with one resistant cancer cell line SKOV3, using MTT (methyl thiazolyl tetrazolium) assay were examined. Hemolytic impacts and cell death mechanisms of the conjugates on human blood and HT1080 cell line were also investigated. The conjugate G2+Pt showed greater toxicity up to 9x and 2x in the sensitive and resistant cell lines (IC(50) comparison, inhibitory concentration) respectively when compared to the parent drug. The G1+Pt conjugate showed greater toxicity only in the sensitive HT1080 (2x) and CT26 (3.7x) cell lines. Moreover, the G1+Pt conjugate was less toxic approximately one third of the cisplatin in SKOV3 after 48 hrs of incubation. In summary, the G2+Pt conjugate had greater toxicity than the G1+Pt conjugate and cisplatin, based on the in vitro results. Approximately the same hemolysis behavior was observed for both conjugates and cisplatin. Both apoptosis and necrosis mechanisms (about 2x more than cisplatin) were attributed to conjugates and cisplatin in a direct correlation between the concentration and the degree of cell death. In conclusion, these conjugates with such high potency and minimum hemolysis would be suitable candidates for use against these cancerous cell lines as efficient and novel antitumor agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.